PRESS RELEASE. Capitainer, a Swedish Medtech company that supplies intelligent solutions for self-sampling of blood and plasma, recently completed a share issue of SEK 31 million with Sciety and its investment syndicate. The investors demonstrated strong interest, and the share issue was fully subscribed in two days. The new capital will be used to increase production capacity and scale up global sales.
“With this successful share issue, we are now well equipped to accelerate both our product development and our sales. I would like to take this opportunity to express my thanks and I am pleased to note the great interest in the company also from new investors. We look forward to exciting times ahead of us and can now focus on making Capitainer a global market leader in self-sampling of blood and plasma,” says Christopher Aulin, CEO of Capitainer.
In February 2020, Capitainer launched its product qDBS, a micro-sampling chip based on DBS (Dried Blood Spot) technology and designed for blood sampling at home. The sampling chip can be sent by regular mail to the laboratory for analysis.
Since its launch, Capitainer qDBS has been validated by more than 25 universities and laboratories, including Harvard, SciLife, Karolinska University Laboratory, St. Thomas Hospital (London), and St. George Hospital (London).
The new capital will primarily be used to increase the production capacity, scale up global sales, and launch the qDPS for collection of plasma samples as well as new qDBS products.
“The majority of all medical decisions are based on blood tests and billions of blood samples are taken every year, but the procedure is expensive and time-consuming. Capitainer offers a reliable solution that in the long run can change the blood sampling procedures and thus the entire way of providing medical care. This opens new opportunities for remote care and also for new areas of use where blood sampling through venipuncture by healthcare professionals today is the only option. The company has a well-defined go-to-market strategy for new regions and a team with solid experience in sales and business development in life science,” says Andreas Lindblom, CEO of Sciety.
About Capitainer
Capitainer was founded in 2016 when Professor Olof Beck at the Department of Clinical Pharmacology, Karolinska Institute, saw the clinic’s overcrowded waiting room and realized that blood sampling in the traditional way would become a huge bottleneck in the future. He contacted Professor Göran Stemme and Associate Professor Niclas Roxhed at KTH Royal Institute of Technology to find a solution to the problem. Together, they developed a revolutionary product design that has several crucial advantages over conventional DBS technology.
In 2019, Christopher Aulin was recruited as CEO of Capitainer. Christopher has extensive experience of sales from, among others, Abbott and was also involved in EDTS’s journey from entrepreneurial phase to profitable company and acquisitions.
Don’t miss out on important news and upcoming events
Do you want to know more about our selected companies and also get invitations to company presentation events where you will have the chance to meet the management?
Subscribe to our newsletter here.
About Sciety
Sciety is the leading Nordic life science and health tech investment syndicate. By combining experience from life science and finance we select promising companies in the industry. We invest our funds in all companies that pass our selection process and offer the investment syndicate to co-invest on the same terms. The syndicate comprises venture capital firms, family offices, and business angels.
Our mission is to help life science innovations to reach their full potential.